Tibet Weixinkang Medicine Co Ltd Net Asset Quality Index
Tibet Weixinkang Medicine Co Ltd net asset quality index. Tibet Weixinkang Medicine Co Ltd (603676) has a Net Asset Quality Index of 78.4% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.96 Billion minus total liabilities of CN¥423.85 Million yields net assets of CN¥1.54 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check earnings quality score of Tibet Weixinkang Medicine Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Tibet Weixinkang Medicine Co Ltd (2013–2025)
Net asset quality index of Tibet Weixinkang Medicine Co Ltd from 2013 to 2025. This chart shows how Tibet Weixinkang Medicine Co Ltd's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of June 2026, the index stands at 78.4%, representing net assets of CN¥1.54 Billion against total assets of CN¥1.96 Billion CNY. See Tibet Weixinkang Medicine Co Ltd book value and equity for net asset value and shareholders' equity analysis.
Tibet Weixinkang Medicine Co Ltd Net Asset Quality Index by Year (2013–2025)
Tibet Weixinkang Medicine Co Ltd net asset quality index by year from 2013 to 2025. The table below presents the year-by-year Net Asset Quality Index for Tibet Weixinkang Medicine Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Tibet Weixinkang Medicine Co Ltd (603676) total market value.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 79.1% | CN¥1.48 Billion | CN¥1.87 Billion | CN¥390.49 Million | ▲ +4.3 pp |
| 2024 | 74.7% | CN¥1.39 Billion | CN¥1.85 Billion | CN¥468.24 Million | ▼ -0.7 pp |
| 2023 | 75.4% | CN¥1.34 Billion | CN¥1.78 Billion | CN¥436.55 Million | ▲ +2.1 pp |
| 2022 | 73.3% | CN¥1.22 Billion | CN¥1.66 Billion | CN¥444.13 Million | ▲ +2.0 pp |
| 2021 | 71.4% | CN¥1.07 Billion | CN¥1.50 Billion | CN¥428.31 Million | ▼ -0.9 pp |
| 2020 | 72.3% | CN¥983.21 Million | CN¥1.36 Billion | CN¥376.85 Million | ▲ +1.0 pp |
| 2019 | 71.3% | CN¥930.05 Million | CN¥1.30 Billion | CN¥374.56 Million | ▼ -1.4 pp |
| 2018 | 72.7% | CN¥897.64 Million | CN¥1.23 Billion | CN¥337.33 Million | ▼ -11.7 pp |
| 2017 | 84.4% | CN¥858.04 Million | CN¥1.02 Billion | CN¥158.58 Million | ▲ +1.2 pp |
| 2016 | 83.2% | CN¥459.42 Million | CN¥552.36 Million | CN¥92.94 Million | ▲ +4.0 pp |
| 2015 | 79.2% | CN¥402.93 Million | CN¥508.75 Million | CN¥105.82 Million | ▲ +0.4 pp |
| 2014 | 78.8% | CN¥286.28 Million | CN¥363.37 Million | CN¥77.09 Million | ▼ -1.3 pp |
| 2013 | 80.1% | CN¥247.78 Million | CN¥309.30 Million | CN¥61.52 Million | — |